Maternal Circulating Placental Growth Factor and Neonatal Metabolic Health Biomarkers in Small for Gestational Age Infants

Hua He, Anne Monique Nuyt, Zhong-Cheng Luo, Francois Audibert, Lise Dubois, Shu-Qin Wei, Haim A Abenhaim, Emmanuel Bujold, Isabelle Marc, Pierre Julien, William D Fraser, 3D Study Group, Hua He, Anne Monique Nuyt, Zhong-Cheng Luo, Francois Audibert, Lise Dubois, Shu-Qin Wei, Haim A Abenhaim, Emmanuel Bujold, Isabelle Marc, Pierre Julien, William D Fraser, 3D Study Group

Abstract

Small for gestational age (SGA) infants are at increased risk of type 2 diabetes in adulthood. It is unknown whether any prenatal biomarkers are helpful for identifying SGA infants with altered metabolic health profile at birth or later life. In a nested study of 162 SGA (birth weight < 10th percentile) and 161 optimal birth weight (25th-75th percentiles) control infants in the 3D (design, develop and discover) birth cohort in Canada, we assessed whether maternal circulating placental growth factor (PlGF), a biomarker of placental function, is associated with metabolic health biomarkers in SGA infants. Main outcomes were cord plasma insulin, proinsulin, insulin-like growth factor-I (IGF-I), leptin, and high-molecular weight (HMW) adiponectin concentrations. Maternal PlGF concentrations at 32-35 weeks of gestation were substantially lower in SGA versus control infants (P < 0.001), so as were cord plasma proinsulin (P = 0.005), IGF-I (P < 0.001), leptin (P < 0.001), and HMW adiponectin (P = 0.002) concentrations. In SGA infants with both low (<25th percentile) and normal maternal PlGF concentrations, cord plasma IGF-I and leptin concentrations were lower than control infants, but the decreases were to a greater extent in SGA infants with low maternal PlGF. Cord blood leptin levels were lower comparing SGA infants with low vs. normal maternal PlGF levels (P = 0.01). SGA infants with low maternal circulating PlGF levels at late gestation were characterized by greater decreases in cord blood IGF-I and leptin concentrations. Maternal circulating PlGF appears to be associated with neonatal metabolic health profile in SGA infants.

Keywords: IGF-I; high-molecular-weight adiponectin; insulin; leptin; neonates; placental growth factor; proinsulin; small for gestational age.

Figures

Figure 1
Figure 1
Selection of small for gestational age (SGA) and control study subjects in the 3D (design, develop, and discover) birth cohort.

References

    1. Su YN, Lee CN, Cheng WF, Shau WY, Chow SN, Hsieh FJ. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol (2001) 97:898–904.10.1097/00006250-200106000-00007
    1. DiSalvo J, Bayne ML, Conn G, Kwok PW, Trivedi PG, Soderman DD, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor. Placenta growth factor heterodimer. J Biol Chem (1995) 270:7717–23.10.1074/jbc.270.13.7717
    1. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med (2012) 44:1–9.10.3858/emm.2012.44.1.025
    1. Torry DS, Ahn H, Barnes EL, Torry RJ. Placenta growth factor: potential role in pregnancy. Am J Reprod Immunol (1999) 41:79–85.10.1111/j.1600-0897.1999.tb00078.x
    1. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol (2001) 184:1267–72.10.1067/mob.2001.113129
    1. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 350:672–83.10.1056/NEJMoa031884
    1. Giguère Y, Massé J, Thériault S, Bujold E, Lafond J, Rousseau F, et al. Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. BJOG (2015) 122:402–10.10.1111/1471-0528.13050
    1. Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol (2007) 109:1316–24.10.1097/01.AOG.0000265804.09161.0d
    1. Fadigas C, Peeva G, Mendez O, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks. Ultrasound Obstet Gynecol (2015) 46:191–7.10.1002/uog.14862
    1. Vrachnis N, Kalampokas E, Sifakis S, Vitoratos N, Kalampokas T, Botsis D, et al. Placental growth factor (PlGF): a key to optimizing fetal growth. J Matern Fetal Neonatal Med (2013) 26:995–1002.10.3109/14767058.2013.766694
    1. Jaquet D, Gaboriau A, Czernichow P, Levy-Marchal C. Insulin resistance early in adulthood in subjects born with intrauterine growth retardation. J Clin Endocrinol Metab (2000) 85:1401–6.10.1210/jc.85.4.1401
    1. Hales CN, Barker DJ. The thrifty phenotype hypothesis. Br Med Bull (2001) 60:5–20.10.1093/bmb/60.1.5
    1. Gluckman PD, Hanson MA. Living with the past: evolution, development, and patterns of disease. Science (2004) 305:1733–6.10.1126/science.1095292
    1. López-Jaramillo P, Gómez-Arbeláez D, López-López J, López-López C, Martínez-Ortega J, Gómez-Rodríguez A, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig (2014) 18:37–45.10.1515/hmbci-2013-0053
    1. Grill V, Dinesen B, Carlsson S, Efendic S, Pedersen O, Ostenson CG. Hyperproinsulinemia and proinsulin-to-insulin ratios in Swedish middle-aged men: association with glycemia and insulin resistance but not with family history of diabetes. Am J Epidemiol (2002) 155:834–41.10.1093/aje/155.9.834
    1. Zhu N, Pankow JS, Ballantyne CM, Couper D, Hoogeveen RC, Pereira M, et al. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. J Clin Endocrinol Metab (2010) 95:5097–104.10.1210/jc.2010-0716
    1. Rajpathak SN, He M, Sun Q, Kaplan RC, Muzumdar R, Rohan TE, et al. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabete (2012) 61:2248–54.10.2337/db11-1488
    1. Fraser WD, Shapiro GD, Audibert F, Dubois L, Pasquier JC, Julien P, et al. 3D cohort study: the integrated research network in perinatology of Quebec and Eastern Ontario. Paediatr Perinat Epidemiol (2016) 30:623–32.10.1111/ppe.12320
    1. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics (2001) 108:E35.10.1542/peds.108.2.e35
    1. Odden N, Mørkrid L. High molecular weight adiponectin dominates in cord blood of newborns but is unaffected by pre-eclamptic pregnancies. Clin Endocrinol (2007) 67:891–6.10.1111/j.1365-2265.2007.02981.x
    1. Luo ZC, Delvin E, Fraser WD, Audibert F, Deal CI, Julien P, et al. Maternal glucose tolerance in pregnancy affects fetal insulin sensitivity. Diabetes Care (2010) 33:2055–61.10.2337/dc10-0819
    1. Luo ZC, Nuyt AM, Delvin E, Audibert F, Girard I, Shatenstein B, et al. Maternal and fetal IGF-I and IGF-II levels, fetal growth, and gestational diabetes. J Clin Endocrinol Metab (2012) 97:1720–8.10.1210/jc.2011-3296
    1. Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression analyses. J Clin Epidemiol (2015) 68:627–36.10.1016/j.jclinepi.2014.12.014
    1. Wortelboer EJ, Koster MP, Kuc S, Eijkemans MJ, Bilardo CM, Schielen PC, et al. Longitudinal trends in fetoplacental biochemical markers, uterine artery pulsatility index and maternal blood pressure during the first trimester of pregnancy. Ultrasound Obstet Gynecol (2011) 38:383–8.10.1002/uog.9029
    1. Schlembach D, Wallner W, Sengenberger R, Stiegler E, Mörtl M, Beckmann MW, et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol (2007) 29:407–13.10.1002/uog.3930
    1. Andrietti S, Carlucci S, Wright A, Wright D, Nicolaides KH. Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in prediction of pre-eclampsia. Ultrasound Obstet Gynecol (2017) 50:221–7.10.1002/uog.17403
    1. Roberts JM, Hubel CA. Oxidative stress in preeclampsia. Am J Obstet Gynecol (2004) 190:1177–8.10.1016/j.ajog.2004.04.001
    1. Turpaev KT. Reactive oxygen species and regulation of gene expression. Biochemistry (Mosc) (2002) 67:281–92.
    1. Gluckman PD, Pinal CS. Regulation of fetal growth by the somatotrophic axis. J Nutr (2003) 133:1741S–6S.10.1093/jn/133.5.1741S
    1. Teague AM, Fields DA, Aston CE, Short KR, Lyons TJ, Chernausek SD. Cord blood adipokines, neonatal anthropometrics and postnatal growth in offspring of Hispanic and native American women with diabetes mellitus. Reprod Biol Endocrinol (2015) 13:68.10.1186/s12958-015-0061-9
    1. Mantzoros CS, Rifas-Shiman SL, Williams CJ, Fargnoli JL, Kelesidis T, Gillman MW. Cord blood leptin and adiponectin as predictors of adiposity in children at 3 years of age: a prospective cohort study. Pediatrics (2009) 123:682–9.10.1542/peds.2008-0343
    1. Simpson J, Smith AD, Fraser A, Sattar N, Lindsay RS, Ring SM, et al. Programming of adiposity in childhood and adolescence: associations with birth weight and cord blood adipokines. J Clin Endocrinol Metab (2017) 102:499–506.10.1210/jc.2016-2342
    1. Boeke CE, Mantzoros CS, Hughes MD, Rifas-Shiman SL, Villamor E, Zera CA, et al. Differential associations of leptin with adiposity across early childhood. Obesity (2013) 21:1430–7.10.1002/oby.20314
    1. Li LJ, Rifas-Shiman SL, Aris IM, Young JG, Mantzoros C, Hivert MF, et al. Associations of maternal and cord blood adipokines with offspring adiposity in project viva: is there an interaction with child age? Int J Obes (2017).10.1038/ijo.2017.256

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren